Tenon Medical, Inc. 8K

Tenon Medical, Inc. announced strong Q4 and full year 2025 financial results, obtained FDA clearance for its next-generation SImmetry+ SI Joint Fusion System, raised additional capital through equity and convertible note financings, and expanded its intellectual property portfolio.

On March 19, 2026, Tenon Medical, Inc. reported its fourth quarter and full year 2025 financial results, highlighting record quarterly revenue of $1.5 million (up 92% year-over-year) and full year revenue of $3.9 million (up 20%), improved gross margins, and a reduced net loss, alongside key strategic milestones including FDA 510(k) clearance for its next-generation SImmetry+ SI Joint Fusion System, completion of initial SImmetry+ procedures at Centers of Excellence, and expanded physician training efforts. The company also strengthened its balance sheet through a $2.85 million At-The-Market PIPE financing completed in Q4 2025 and subsequently closed a private placement of senior convertible notes for gross proceeds of $4.3 million in March 2026 to fund commercial expansion, product launches, and clinical studies, while further bolstering its intellectual property portfolio with multiple Notices of Allowance from the U.S. Patent and Trademark Office. Management scheduled a conference call for March 19, 2026 to discuss these results and provide a corporate update.

Filing Facts

CIK

1560293

Ticker

-

Form

8K

Source Type

sec

Accession

0001213900-26-031840

Alert Tier

7